Evidence map›Paper›PMID 33796822›Full record

ArticleCancer drug resistance (Alhambra, Calif.)2020

Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy.

Serkan Yaman, Uday Chintapula, Edgar Rodriguez, Harish Ramachandramoorthy, Kytai T Nguyen

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer drug resistance (Alhambra, Calif.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Boosting Lipofection Efficiency Through Enhanced Membrane Fusion Mechanisms.International journal of molecular sciences · 2024
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Serkan YamanDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76010, USA.
Uday ChintapulaDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76010, USA.
Edgar RodriguezDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76010, USA.
Harish RamachandramoorthyDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76010, USA.
Kytai T NguyenDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76010, USA.
The University of Texas at Arlington · USThe University of Texas Southwestern Medical Center · US

Funding

Interdisciplinary Training in Nanotechnology for Cardiovascular and Lung Diseases in North TexasT32HL134613 · NHLBI · UNIVERSITY OF TEXAS ARLINGTON · PI NGUYEN, KYTAI TRUONG · 2017 to 2021
$1.1M
NHLBI NIH HHS T32 HL134613
6 · The paper itself

Abstract

Nanotechnology-based drug delivery platforms have been developed over the last two decades because of their favorable features in terms of improved drug bioavailability and stability. Despite recent advancement in nanotechnology platforms, this approach still falls short to meet the complexity of biological systems and diseases, such as avoiding systemic side effects, manipulating biological interactions and overcoming drug resistance, which hinders the therapeutic outcomes of the NP-based drug delivery systems. To address these issues, various strategies have been developed including the use of engineered cells and/or cell membrane-coated nanocarriers. Cell membrane receptor profiles and characteristics are vital in performing therapeutic functions, targeting, and homing of either engineered cells or cell membrane-coated nanocarriers to the sites of interest. In this context, we comprehensively discuss various cell- and cell membrane-based drug delivery approaches towards cancer therapy, the therapeutic potential of these strategies, and the limitations associated with engineered cells as drug carriers and cell membrane-associated drug nanocarriers. Finally, we review various cell types and cell membrane receptors for their potential in targeting, immunomodulation and overcoming drug resistance in cancer.

Indexed as

cancer drug resistancecell-mediated drug deliveryCell membrane-based drug deliverydrug carriersmembrane receptorsnanoparticles

Identifiers

PMID33796822
PMCPMC8011581
OpenAlexW3097105711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.